128 Participants Needed

Prebiotic Supplement for Acute GVHD

ML
AP
LH
Overseen ByLauren Hill
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell transplant. The study has two two parts. In phase 1, the best dose of GOS will be evaluated. In phase 2, using the best dose of GOS, participants will be randomized to receive GOS or a placebo (maltodextrin, a common food additive that is not known to affect the microbiome) so that the effect of GOS can be determined.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot be on active treatment with other prebiotics, probiotics, herbal supplements, or antibiotics (except preventive antibiotics) when you enroll.

What data supports the effectiveness of the treatment Galacto-oligosaccharide for acute GVHD?

Research shows that galacto-oligosaccharides (GOS) can promote the growth of beneficial gut bacteria, which may help protect the intestinal barrier during infections. Additionally, GOS has been shown to have a preventive effect against colorectal cancer in animal studies, suggesting potential benefits for gut health.12345

Is the prebiotic supplement Galacto-oligosaccharide safe for humans?

Galacto-oligosaccharides (GOS) are generally considered safe for humans, as confirmed by the Food and Drug Administration. They are widely used in food products and have been shown to have beneficial effects on gut health without significant safety concerns.678910

How is the prebiotic treatment Galacto-oligosaccharide unique for acute GVHD?

Galacto-oligosaccharide (GOS) is unique because it is a prebiotic that specifically promotes the growth of beneficial gut bacteria like bifidobacteria, which can help improve gut health and potentially modulate immune responses. This is different from traditional treatments for acute GVHD, which often focus on suppressing the immune system rather than enhancing gut microbiota.411121314

Research Team

AS

Anthony Sung, MD

Principal Investigator

Duke Health

MH

Mitchell Horwitz, MD

Principal Investigator

Duke Health

Eligibility Criteria

Adults aged 18-80 planning to undergo a stem cell transplant for cancer or other illnesses, with a good performance status. Not eligible if using antibiotics (except prophylactic), prebiotics, probiotics, herbal supplements unless stopped before joining; also excluded if pregnant/lactating, have certain digestive conditions, or are in specific other GVHD trials.

Inclusion Criteria

I am mostly able to care for myself and carry out daily activities.
I am between 18 and 80 years old.
I am planning to have a stem cell transplant from a donor.

Exclusion Criteria

I am enrolled in a study for GVHD or not in any conflicting trials.
I am experiencing moderate to severe stomach or intestinal issues.
I am currently taking antibiotics for an infection.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase I Treatment

Participants receive GOS at dose levels 0.75g, 1.5g, and 2.9g/day to determine the provisional maximum tolerated dose (pMTD)

Approximately 30 days
Daily administration

Phase II Treatment

Participants receive GOS or placebo (maltodextrin) at determined pMTD from about 30 days before transplant to about 4 weeks after transplant

Approximately 8 weeks
Daily administration

Follow-up

Participants are monitored for safety and effectiveness after treatment, including overall survival and incidence of chronic GVHD

Up to 730 days
Chart reviews at Day 365 and Day 730

Treatment Details

Interventions

  • Galacto-oligosaccharide
  • Maltodextrin
Trial OverviewThe trial is testing galacto-oligosaccharide (GOS), a dietary supplement thought to improve gut bacteria and prevent graft-versus-host disease after stem cell transplants. Participants will first help find the best dose of GOS and then be randomly given either GOS or maltodextrin (placebo) to see its effects.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Galacto-oligosaccharideExperimental Treatment1 Intervention
Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant. Phase II: Subjects will receive GOS, at dose levels 0.25\*MTD, 0.5\*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant.
Group II: MaltodextrinPlacebo Group1 Intervention
Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.

Galacto-oligosaccharide is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Galacto-oligosaccharides for:
  • Infant nutrition
  • Food additive
🇺🇸
Approved in United States as Galacto-oligosaccharides for:
  • Dietary supplement
  • Food additive

Find a Clinic Near You

Who Is Running the Clinical Trial?

Duke University

Lead Sponsor

Trials
2,495
Recruited
5,912,000+

Findings from Research

In a study of 104 children aged 9-24 months with acute diarrhea, a mixture of prebiotics did lead to a slight decrease in the number of stools and an increase in stool consistency, but these changes were not clinically significant.
The only notable immune response observed was a decrease in TNF-α levels in the supplemented group, indicating some immune modulation, but overall, prebiotic supplementation did not significantly affect the clinical course of acute diarrhea.
Short-term effect of prebiotics administration on stool characteristics and serum cytokines dynamics in very young children with acute diarrhea.Vaisman, N., Press, J., Leibovitz, E., et al.[2021]
In a study involving 12 healthy adults, the intake of galacto-oligosaccharides (GOS) during and after amoxicillin treatment showed a trend towards higher levels of beneficial bifidobacteria compared to a placebo, suggesting a potential role in gut microbiota recovery.
GOS intake also led to a significant increase in butyrate levels in fecal samples, indicating enhanced metabolic activity of the microbiota, which supports the idea that GOS can help restore gut health after antibiotic treatment.
Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment.Ladirat, SE., Schoterman, MH., Rahaoui, H., et al.[2014]
Galactooligosaccharides (GOS) significantly increased the growth of beneficial Lactobacillus strains in both piglets and mice, which helped alleviate Salmonella infections, indicating their potential as a prebiotic for gut health.
Different Lactobacillus strains showed unique protective mechanisms: L. delbrueckii reduced intestinal inflammation by inhibiting specific signaling pathways, while L. johnsonii prevented Salmonella from adhering to gut cells, highlighting the varied roles of GOS-enriched probiotics in intestinal health.
Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection.Wu, Y., Zhang, X., Liu, X., et al.[2023]

References

Short-term effect of prebiotics administration on stool characteristics and serum cytokines dynamics in very young children with acute diarrhea. [2021]
Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment. [2014]
Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection. [2023]
Novel Combination of Prebiotics Galacto-Oligosaccharides and Inulin-Inhibited Aberrant Crypt Foci Formation and Biomarkers of Colon Cancer in Wistar Rats. [2018]
Prebiotic effect during the first year of life in healthy infants fed formula containing GOS as the only prebiotic: a multicentre, randomised, double-blind and placebo-controlled trial. [2022]
Galactooligosaccharides: Synthesis, metabolism, bioactivities and food applications. [2023]
Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. [2019]
Development of hypoallergenic galacto-oligosaccharides on the basis of allergen analysis. [2014]
A one-generation reproduction toxicity study in rats treated orally with a novel galacto-oligosaccharide. [2015]
Impact of Novel Prebiotic Galacto-Oligosaccharides on Various Biomarkers of Colorectal Cancer in Wister Rats. [2018]
11.United Statespubmed.ncbi.nlm.nih.gov
Galacto-Oligosaccharides: Production, Properties, Applications, and Significance as Prebiotics. [2021]
Profile diversity of galacto-oligosaccharides from disaccharides to hexasaccharides by porous graphitic carbon liquid chromatography-orbitrap tandem mass spectrometry. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Functional oligosaccharides: application and manufacture. [2011]
14.United Statespubmed.ncbi.nlm.nih.gov
Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. [2021]